U.K., Drug Companies Announce $100M Venture Capital Fund For Dementia Research, As U.N. Opens First-Ever Dementia Conference

Financial Times: Dementia research boosted by $100m venture capital fund
“Research into dementia is to be boosted by a $100m venture capital fund backed by the U.K. government and several of the world’s biggest pharmaceuticals companies…” (Ward, 3/17).

Reuters: Dementia drug research aided by $100 million venture capital fund
“…The global Dementia Discovery Fund is unique in focusing on a single difficult to treat disorder and in bringing together industry and government. Drug companies involved include GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Pfizer, and Biogen Idec…” (Hirschler, 3/17).

U.N. News Centre: Countries urged to make dementia public health priority as U.N. conference opens in Geneva
“The United Nations World Health Organization (WHO) today opened the first-ever Ministerial Conference on Global Action Against Dementia by reminding health ministers from around the world, experts, and civil society representatives that every four seconds someone is diagnosed with the incurable disease…” (3/16).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.